MCET News 08/25/2014 19:22:37 $MCET Agreed, tob99
Post# of 64200
Posted On: 08/25/2014 8:22:43 PM
MCET News 08/25/2014 19:22:37 $MCET
Agreed, tob999. Simply stated, the technology that MultiCell has developed would not only effectively target cancer cells, but also provide the patient with some sort of preventive shield against the formation of new tumors.
Quote:
This is a major league patent if these results can be replicated in humans:
Quote:
In mouse cancer models, the combination of MCT-465, a dsRNA therapeutic, and MCT-475, an IgP therapeutic, not only induced the animal's immune system to eradicate the engrafted tumor, but upon rechallenge with tumor cells, no new tumors developed indicating the animal had developed protective anti-tumoral immunity
MCET
This is a major league patent if these results can be replicated in humans:
Quote:
In mouse cancer models, the combination of MCT-465, a dsRNA therapeutic, and MCT-475, an IgP therapeutic, not only induced the animal's immune system to eradicate the engrafted tumor, but upon rechallenge with tumor cells, no new tumors developed indicating the animal had developed protective anti-tumoral immunity
MCET Stock Message Board http://investorshangout.com/Multicell-Techs-Inc-MCET-64069/
MultiCell Technologies Granted U.S. Patent Covering Therapeutics Which Fight Virus Infection And Cancer
Aug 25, 2014 7:51 AM CT
MultiCell Technologies Granted U.S. Patent Covering Therapeutics Which Fight Virus Infection And Cancer PR Newswire WOONSOCKET, R.I., Aug. 25, 2014 WOONSOCKET, R.I., Aug. 25, 2014 /PRNewswire/ --MultiCell Technologies, Inc. (OTC: MCET) has been issued U.S. patent 8,809,290 covering novel drug compositions and platform technologies which redirect the immune system response to protect against highly virulent virus infection and cancer. These novel drug compositions consisting of noncoding doubled stranded RNA (dsRNA) molecules and recombinant immunoglobulin-peptide (IgP) molecules demonstrate unique immune stimulating activity, and the ability to present peptide antigens to immune cells resulting in protective anti-tumoral and anti-viral immunity. In mouse cancer models, the combination of MCT-465, a dsRNA therapeutic, and MCT-475, an IgP therapeutic, not only induced the animal's immune system to eradicate the engrafted tumor, but upon rechallenge with tumor cells, no new tumors developed indicating the animal had developed protective anti-tumoral immunity. Tumor rejection and protection against similar and new tumor variants was found to also be associated with specific, overall expansion of cytokine producing cells. This finding indicates a broadening of the repertoire of anti-tumor immune cells and the development of immune memory in the animal. Mice immunized with MCT-465 and MCT-475 resulted in the priming of an immune response capable of limiting the replication of virus subsequent to further virus infectious challenge. During viral infection, specific immune system cells begin to proliferate and differentiate which defines the adaptive immune response to the infection. In mouse models, administration of MCT-465 and MCT-475 greatly enhanced the generation of interferon gamma (IFN?) and interleukin-2 (IL-2) producing virus antigen-specific T-cells resulting in significantly reduced virus levels present in the animal. MultiCell is developing MCT-465 and MCT-475 for the treatment of hepatitis B virus infection and hepatitis C virus infection, and for the treatment of certain cancers. Chronic hepatitis B and chronic hepatitis C virus infection are recognized as major factors worldwide that increase the risk of hepatocellular carcinoma. According to the U.S. National Cancer Institute (NCI), chronic hepatitis B virus infection and chronic hepatitis C virus infection account for about 30% to 40% of all reported USA cases of hepatocellular carcinoma. Treatment of hepatocellular carcinoma, the most common form of primary liver cancer, represents a major unmet medical need. Hepatocellular carcinoma is a leading cause of cancer death worldwide, and is the fourth most common cancer in the world. Over 1 million cases of hepatocellular carcinoma are reported annually worldwide. Current approaches for treatment of hepatocellular carcinoma are of limited efficacy. According to the NCI, only 16% of patients diagnosed with primary liver cancer survive longer than 5 years. MultiCell is also developing MCT-485, a very small dsRNA therapeutic, thought to target cancer by delivering a cytotoxic effect to only those cells having the highest tumor initiating capability that are part of the cancerous process such as cancer stem cells and tumor initiating cells. MCT-485 appears to have no effect on cells not directly involved in the process of relapse, progression and metastasis of cancer. MCT-485 appears to exert a preferential biological activity on liver cancer cells while showing no effect on normal liver cells. About MultiCell Technologies, Inc. MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools for the treatment of primary multiple sclerosis-related fatigue and cancer
agreed 100%...a patent for CANCER....multi days RNNER...also imho....
Patent Assignment Abstract of Title
NOTE:Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staf
Total Assignments: 1
Patent #:
8809290
Issue Dt:
08/19/2014
Application #:
13078119
Filing Dt:
04/01/2011
Publication #:
20110274705
Pub Dt:
11/10/20
Inventors:
Adrian Bot, Lilin Wang, Dan Joseph Smith, Luis A. Dellamary et al
Title:
METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF T CELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS
Assignment:
Reel/Frame:
032095/0584
Recorded: 01/30/2014
Pages: 7
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignors:
WANG, LILIN
Exec Dt:
08/13/2012
DELLAMARY, LUIS A.
Exec Dt:
08/16/2012
PHILLIPS, WILLIAM JOSEPH, JR.
Exec Dt:
08/16/2012
SMITH, DAN JOSEPH
Exec Dt:
08/16/2012
BOT, ADRIAN
Exec Dt:
08/22/2012
Assignee:
MULTICELL IMMUNOTHERAPEUTICS, INC.
68 CUMBERLAND STREET
SUITE 301
WOONSOCKET, RHODE ISLAND 02895
Correspondent:
KEVIN M. FARRELL
100 SUMMER STREET
SUITE 2250
BOSTON, MA 02110
You're welcome. The interesting thing is that in most industries, a company would need to have significant revenues, or a well known brand name, to be of any value to a potential suitor.
But in the pharmaceutical business, it is a whole different ball game. The right research & development combined with the right patent(s) can result in a huge buyout offer from one of the big players. Sometimes they'll make a huge offer just to keep one of their major competitors from getting the patent(s).
I think we might see some excitement here in the coming days.
A always, simply my opinion.
Quote:
thx!..very educational...WOW!
MCET
Imagine a buyout offer .. Penny land
thx!..very educational...WOW!
Recently Merck tendered an offer of more than $3 billion to acquire Idenix Pharmaceuticals Inc . Idenix is a 'biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases'.
According to their 10-K filing, Idenix only had revenue of $469,000 for all of CY 2013 (see link below for filing), no revenue for Q1 or Q2 of 2014 (according to google finance), and has been bleeding money for several years.
Yet Merck has tendered an offer valued at more than $3 billion, because of the patents they own and the research they have conducted.
So here's an intriguing piece of info... Merck only derived about 3% of its revenue in Q1 2013 from Cancer related drugs. When an industry giant is weak in a particular area, they often use acquisitions to strengthen their weakest areas.
It would seem plausible that a company like Merck, who has already demonstrated their willingness and desire to acquire smaller companies, might eventually be willing to buy a company like MultiCell (for their research performed and patents held). And based upon the $3 billion Merck will be paying for Idenix (with little or no recent revenue), any possible offer could be rich indeed. Could you imagine how an OTC stock would react if Merck expressed some interest in owning them?
As always, simply my opinion.
Merck Completes Tender Offer to Acquire Idenix
http://www.marketwatch.com/story/merck-comple...2014-08-05
Why Did Merck Pay Such A Huge Premium For Idenix?
http://www.forbes.com/sites/greatspeculations...or-idenix/
Link to Idenix Pharmaceuticals Inc 2013 10-K:
http://www.sec.gov/Archives/edgar/data/109364...-index.htm
MCET
Tomorrow another 50% up
ok, the same to u!
lol!
Actually, it is not directly assigned to MCET, I'd take a look.
Missed Simple Simon today. We can now say his bashing ammunition has been narrowed by at least 2 things.
1. MCET does absolutely nothing
2. No patents in MCET's name. (This one is)
Looks like shorting happened on MCET. Short covering tomorrow
* * $MCET Video Chart 8-25-14 * *
Link to Video - click here to watch the technical chart video
realistically this attempts to go touch .0020 - .0022 the high from the last run, will likely fail there....
700m vol says this is more then one day play.
Eow high.....guesses? Nice base here
IP (intellectual property) on the production of wine by the glass was offered up for an investment on Shark Tank, and I recall one of the sharks offering several million dollars (with an intent to license out the patent rights).
So how much might one of the big pharma boys (such as Merck, Pfizer, etc) be willing to pay for the patent(s) which not only effectively target cancer cells, but also provide the patient with some sort of preventive shield against the formation of new tumors? I would think the starting price would have to be at least in the tens of millions of dollars, if not more.
Here's an exerpt from today's PR:
'In mouse cancer models, the combination of MCT-465, a dsRNA therapeutic, and MCT-475, an IgP therapeutic, not only induced the animal's immune system to eradicate the engrafted tumor, but upon rechallenge with tumor cells, no new tumors developed indicating the animal had developed protective anti-tumoral immunity. Tumor rejection and protection against similar and new tumor variants was found to also be associated with specific, overall expansion of cytokine producing cells. This finding indicates a broadening of the repertoire of anti-tumor immune cells and the development of immune memory in the animal'
As always, simply my opinion.
MCET
Agreed, tob999. Simply stated, the technology that MultiCell has developed would not only effectively target cancer cells, but also provide the patient with some sort of preventive shield against the formation of new tumors.
Quote:
This is a major league patent if these results can be replicated in humans:
Quote:
In mouse cancer models, the combination of MCT-465, a dsRNA therapeutic, and MCT-475, an IgP therapeutic, not only induced the animal's immune system to eradicate the engrafted tumor, but upon rechallenge with tumor cells, no new tumors developed indicating the animal had developed protective anti-tumoral immunity
MCET
This is a major league patent if these results can be replicated in humans:
Quote:
In mouse cancer models, the combination of MCT-465, a dsRNA therapeutic, and MCT-475, an IgP therapeutic, not only induced the animal's immune system to eradicate the engrafted tumor, but upon rechallenge with tumor cells, no new tumors developed indicating the animal had developed protective anti-tumoral immunity
MCET Stock Message Board http://investorshangout.com/Multicell-Techs-Inc-MCET-64069/
MultiCell Technologies Granted U.S. Patent Covering Therapeutics Which Fight Virus Infection And Cancer
Aug 25, 2014 7:51 AM CT
MultiCell Technologies Granted U.S. Patent Covering Therapeutics Which Fight Virus Infection And Cancer PR Newswire WOONSOCKET, R.I., Aug. 25, 2014 WOONSOCKET, R.I., Aug. 25, 2014 /PRNewswire/ --MultiCell Technologies, Inc. (OTC: MCET) has been issued U.S. patent 8,809,290 covering novel drug compositions and platform technologies which redirect the immune system response to protect against highly virulent virus infection and cancer. These novel drug compositions consisting of noncoding doubled stranded RNA (dsRNA) molecules and recombinant immunoglobulin-peptide (IgP) molecules demonstrate unique immune stimulating activity, and the ability to present peptide antigens to immune cells resulting in protective anti-tumoral and anti-viral immunity. In mouse cancer models, the combination of MCT-465, a dsRNA therapeutic, and MCT-475, an IgP therapeutic, not only induced the animal's immune system to eradicate the engrafted tumor, but upon rechallenge with tumor cells, no new tumors developed indicating the animal had developed protective anti-tumoral immunity. Tumor rejection and protection against similar and new tumor variants was found to also be associated with specific, overall expansion of cytokine producing cells. This finding indicates a broadening of the repertoire of anti-tumor immune cells and the development of immune memory in the animal. Mice immunized with MCT-465 and MCT-475 resulted in the priming of an immune response capable of limiting the replication of virus subsequent to further virus infectious challenge. During viral infection, specific immune system cells begin to proliferate and differentiate which defines the adaptive immune response to the infection. In mouse models, administration of MCT-465 and MCT-475 greatly enhanced the generation of interferon gamma (IFN?) and interleukin-2 (IL-2) producing virus antigen-specific T-cells resulting in significantly reduced virus levels present in the animal. MultiCell is developing MCT-465 and MCT-475 for the treatment of hepatitis B virus infection and hepatitis C virus infection, and for the treatment of certain cancers. Chronic hepatitis B and chronic hepatitis C virus infection are recognized as major factors worldwide that increase the risk of hepatocellular carcinoma. According to the U.S. National Cancer Institute (NCI), chronic hepatitis B virus infection and chronic hepatitis C virus infection account for about 30% to 40% of all reported USA cases of hepatocellular carcinoma. Treatment of hepatocellular carcinoma, the most common form of primary liver cancer, represents a major unmet medical need. Hepatocellular carcinoma is a leading cause of cancer death worldwide, and is the fourth most common cancer in the world. Over 1 million cases of hepatocellular carcinoma are reported annually worldwide. Current approaches for treatment of hepatocellular carcinoma are of limited efficacy. According to the NCI, only 16% of patients diagnosed with primary liver cancer survive longer than 5 years. MultiCell is also developing MCT-485, a very small dsRNA therapeutic, thought to target cancer by delivering a cytotoxic effect to only those cells having the highest tumor initiating capability that are part of the cancerous process such as cancer stem cells and tumor initiating cells. MCT-485 appears to have no effect on cells not directly involved in the process of relapse, progression and metastasis of cancer. MCT-485 appears to exert a preferential biological activity on liver cancer cells while showing no effect on normal liver cells. About MultiCell Technologies, Inc. MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools for the treatment of primary multiple sclerosis-related fatigue and cancer
agreed 100%...a patent for CANCER....multi days RNNER...also imho....
Patent Assignment Abstract of Title
NOTE:Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staf
Total Assignments: 1
Patent #:
8809290
Issue Dt:
08/19/2014
Application #:
13078119
Filing Dt:
04/01/2011
Publication #:
20110274705
Pub Dt:
11/10/20
Inventors:
Adrian Bot, Lilin Wang, Dan Joseph Smith, Luis A. Dellamary et al
Title:
METHODS AND COMPOSITIONS TO GENERATE AND CONTROL THE EFFECTOR PROFILE OF T CELLS BY SIMULTANEOUS LOADING AND ACTIVATION OF SELECTED SUBSETS OF ANTIGEN PRESENTING CELLS
Assignment:
Reel/Frame:
032095/0584
Recorded: 01/30/2014
Pages: 7
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignors:
WANG, LILIN
Exec Dt:
08/13/2012
DELLAMARY, LUIS A.
Exec Dt:
08/16/2012
PHILLIPS, WILLIAM JOSEPH, JR.
Exec Dt:
08/16/2012
SMITH, DAN JOSEPH
Exec Dt:
08/16/2012
BOT, ADRIAN
Exec Dt:
08/22/2012
Assignee:
MULTICELL IMMUNOTHERAPEUTICS, INC.
68 CUMBERLAND STREET
SUITE 301
WOONSOCKET, RHODE ISLAND 02895
Correspondent:
KEVIN M. FARRELL
100 SUMMER STREET
SUITE 2250
BOSTON, MA 02110
You're welcome. The interesting thing is that in most industries, a company would need to have significant revenues, or a well known brand name, to be of any value to a potential suitor.
But in the pharmaceutical business, it is a whole different ball game. The right research & development combined with the right patent(s) can result in a huge buyout offer from one of the big players. Sometimes they'll make a huge offer just to keep one of their major competitors from getting the patent(s).
I think we might see some excitement here in the coming days.
A always, simply my opinion.
Quote:
thx!..very educational...WOW!
MCET
Imagine a buyout offer .. Penny land
thx!..very educational...WOW!
Recently Merck tendered an offer of more than $3 billion to acquire Idenix Pharmaceuticals Inc . Idenix is a 'biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases'.
According to their 10-K filing, Idenix only had revenue of $469,000 for all of CY 2013 (see link below for filing), no revenue for Q1 or Q2 of 2014 (according to google finance), and has been bleeding money for several years.
Yet Merck has tendered an offer valued at more than $3 billion, because of the patents they own and the research they have conducted.
So here's an intriguing piece of info... Merck only derived about 3% of its revenue in Q1 2013 from Cancer related drugs. When an industry giant is weak in a particular area, they often use acquisitions to strengthen their weakest areas.
It would seem plausible that a company like Merck, who has already demonstrated their willingness and desire to acquire smaller companies, might eventually be willing to buy a company like MultiCell (for their research performed and patents held). And based upon the $3 billion Merck will be paying for Idenix (with little or no recent revenue), any possible offer could be rich indeed. Could you imagine how an OTC stock would react if Merck expressed some interest in owning them?
As always, simply my opinion.
Merck Completes Tender Offer to Acquire Idenix
http://www.marketwatch.com/story/merck-comple...2014-08-05
Why Did Merck Pay Such A Huge Premium For Idenix?
http://www.forbes.com/sites/greatspeculations...or-idenix/
Link to Idenix Pharmaceuticals Inc 2013 10-K:
http://www.sec.gov/Archives/edgar/data/109364...-index.htm
MCET
Tomorrow another 50% up
ok, the same to u!
lol!
Actually, it is not directly assigned to MCET, I'd take a look.
Missed Simple Simon today. We can now say his bashing ammunition has been narrowed by at least 2 things.
1. MCET does absolutely nothing
2. No patents in MCET's name. (This one is)
Looks like shorting happened on MCET. Short covering tomorrow
* * $MCET Video Chart 8-25-14 * *
Link to Video - click here to watch the technical chart video
realistically this attempts to go touch .0020 - .0022 the high from the last run, will likely fail there....
700m vol says this is more then one day play.
Eow high.....guesses? Nice base here
IP (intellectual property) on the production of wine by the glass was offered up for an investment on Shark Tank, and I recall one of the sharks offering several million dollars (with an intent to license out the patent rights).
So how much might one of the big pharma boys (such as Merck, Pfizer, etc) be willing to pay for the patent(s) which not only effectively target cancer cells, but also provide the patient with some sort of preventive shield against the formation of new tumors? I would think the starting price would have to be at least in the tens of millions of dollars, if not more.
Here's an exerpt from today's PR:
'In mouse cancer models, the combination of MCT-465, a dsRNA therapeutic, and MCT-475, an IgP therapeutic, not only induced the animal's immune system to eradicate the engrafted tumor, but upon rechallenge with tumor cells, no new tumors developed indicating the animal had developed protective anti-tumoral immunity. Tumor rejection and protection against similar and new tumor variants was found to also be associated with specific, overall expansion of cytokine producing cells. This finding indicates a broadening of the repertoire of anti-tumor immune cells and the development of immune memory in the animal'
As always, simply my opinion.
MCET
(0)
(0)